



international bowel  
**ULTRASOUND GROUP**



**G E N I U S**

Gastroenterological Network for Intestinal Ultrasonography

# Intestinal Ultrasound in IBD

## Why, when and how?

**Joana Torres, MD, PhD**

Hospital Beatriz Ângelo, Loures, Portugal  
Faculdade de Medicina, Lisbon University



# Introduction

- Ileocolonoscopy is considered the gold standard for grading inflammation and mapping disease extent in ulcerative colitis and ileocolonic Crohn's disease
- Cross-sectional imaging is recommended at diagnosis and during follow-up
- With the wider adoption of tight monitoring in IBD, and the emergence of new therapeutic goals, there has been an increasing role for cross-sectional imaging in IBD




# Ultrasound in IBD – Why?

- Accurate tool
  - Comparable to ileocolonoscopy to assess disease activity and extent
  - Comparable to other imaging modalities (CT and MRI) to assess disease phenotype and presence of complications
- Good correlation with mucosal healing both in CD and UC
- Non-invasive, no radiation involved, no prep needed
- Inexpensive
- Widely available
- Can be undertaken as point of care to allow real-time decision making
  - Expedite colonoscopy if suspicion for IBD based on IUS
  - May inform response to a given therapy – allows optimization

# Ultrasound in IBD – Why?

- Very good patient acceptance



## Ultrasound in IBD – Why?

- Patient-centered monitoring tool
  - Patients can be actively involved in the examination and the clinician can use the experience as an opportunity to educate and engage the patient
  - Immediate feedback about disease activity

# Ultrasound in IBD – Barriers to implementation

- Lack of training opportunity
- A perception of operator dependence
  - Misconception:
    - ❖ BWT excellent correlation and interobserver agreement for disease activity
- No single accepted US score
- Need for more carefully conducted prospective studies on how to best use IUS in IBD

## Ultrasound in IBD – When?

- Initial diagnosis in suspected IBD
- Detection of complications
- Postoperative recurrence
- Perianal disease activity (transperineal ultrasound)
- **Monitoring disease activity / response to treatment**
  - **To guide therapeutic decisions**
- **Monitor disease progression**

# IUS – increasing role in our therapeutic algorithms

## Tight monitoring



### ECCO-ESGAR statement

Endoscopic or **transmural response** to therapy should be evaluated within 6 months following initiation of therapy (EL2).

## Treat to target



### Transmural healing


- **a new therapeutic target in CD? (and UC?)**



# Disease monitoring – Crohn's disease

## Reduction of bowel wall thickness on treatment

### TRUST Study



234 adult patients with CD who experienced a flare

### Ultrasound agrees with endoscopic healing

$K=0.73$ ,  $p<0.001$  (N=162)

# Disease monitoring – Crohn's disease

## STARDUST IUS substudy

### Patient inclusion criteria:


Active CD: CDAI  $\geq 220$  and  $\leq 450$  AND SES-CD  $\geq 3$ . Biologic-naïve or exposed to 1 biologic only

### STARDUST IUS SUB-STUDY:

In selected centers

### Exclusion criteria:


affected bowel segment  
not visible with IUS



# Disease monitoring – Crohn's disease


## STARDUST IUS substudy - IUS response and transmural healing over time

- **IUS response** →  $\geq 25\%$  BWT reduction
- **IUS transmural healing** → BWT normalisation, Doppler signal  $\leq 1$ , normal stratification and absence of i-fat



# Disease monitoring – Ulcerative colitis


- Multicenter, prospective, observational study (TRUST&UC)
- 178 UC patients experiencing a flare
- **Primary outcome:** proportion of those patients that had a clinical response and normalization of BWT by W12



# Transmural healing: the ultimate goal in CD?




Imaging identifies key disease features used to risk phenotype and stratify patients



# Transmural healing

## CT or MR-Enterography improvement



**Less surgery, hospitalization, corticosteroid use  
in Crohn's disease patients with radiographic response**

Improved lesions on CTE or MRE were defined as those with decreased enhancement or length of disease, without worsening of the other disease parameters of active inflammation (enhancement, length, dilated vasa recta/comb sign, perienteric inflammation (edema, phlegmon, or abscess), or fistulizing (internal penetrating) disease).

# Disease monitoring and treat to target with IUS

## Burning questions

- What is the reduction of BWT during induction that can predict long-term remission?
- How often should we perform IUS?
- What degree of persistent BWT should trigger therapy optimization/discontinuation/switching?
- What is the degree of ultrasonographic response is associated with durable clinical remission?
- Can all patients achieve transmural healing?
- Can we use IUS to monitor bowel damage over time?

# Ultrasound in IBD – How?

## Module 1

IBUS Hands-on Workshop

## Module 2

Hands-on Training

## Module 3

ECCO-ESGAR Advanced Workshop



## Module 1 - Every session will include:

- **Theoretical talk** (plenary session) – all participants + speaker(s)
  - Please share your questions at the end of the module in the Q&A session
  
- **Hands-on Session** (break-out rooms – 6/7 participants + 1 tutor per room)
  - Live demonstrations + still images & cineloop discussion
  
- **Q&A session** (plenary session) – all participants + speaker + moderator
  - Interactive discussion

## Example:

**4:10 – 4:25 pm**

**How to perform IUS**

Carolina Palmela

**4:25 – 5:05 pm**

**Hands-On #1: How to perform IUS**

Healthy Volunteers

**5:05 – 5:15 pm**

**Q&A: How to perform IUS**

**4:10 – 4:25 pm**

Theoretical talk

(15 min)

**4:25 – 5:05 pm**

Room  
1

Room  
2

Room  
3

Room  
4

Room  
5

Room  
6

(40 min)

**5:05 – 5:15 pm**

Q&A session

(10 min)

**Enjoy the workshop!**